The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer “Omics”

Mass spectrometry (MS) is an essential analytical technology on which the emerging omics domains; such as genomics; transcriptomics; proteomics and metabolomics; are based. This quantifiable technique allows for the identification of thousands of proteins from cell culture; bodily fluids or tissue using either global or targeted strategies; or detection of biologically active metabolites in ultra amounts. The routine performance of MS technology in the oncological field provides a better understanding of human diseases in terms of pathophysiology; prevention; diagnosis and treatment; as well as development of new biomarkers; drugs targets and therapies. In this review; we argue that the recent; successful advances in MS technologies towards cancer omics studies provides a strong rationale for its implementation in biomedicine as a whole.

[1]  G. Calin,et al.  Noncoding RNAs in Lung Cancer Angiogenesis , 2017 .

[2]  D. Hochstrasser,et al.  Evaluation and identification of dioxin exposure biomarkers in human urine by high-resolution metabolomics, multivariate analysis and in vitro synthesis. , 2016, Toxicology letters.

[3]  Z. Kokot,et al.  Mass spectrometry as a tool for biomarkers searching in gynecological oncology. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  S. Hanash,et al.  Application of proteomics to cancer early detection. , 2011, Cancer journal.

[5]  Oliver M. Bernhardt,et al.  Optimization of Experimental Parameters in Data-Independent Mass Spectrometry Significantly Increases Depth and Reproducibility of Results* , 2017, Molecular & Cellular Proteomics.

[6]  L. Kowalski,et al.  Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches , 2012, Front. Pharmacol..

[7]  Ishtiaq Rehman,et al.  The Use of Proteomics in Urological Research , 2005 .

[8]  I. Lossos,et al.  MiR-181 family-specific behavior in different cancers: a meta-analysis view , 2018, Cancer and Metastasis Reviews.

[9]  H. Schiebel,et al.  Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. , 1996, Clinical chemistry.

[10]  Qin Fu,et al.  Preparation of proteins and peptides for mass spectrometry analysis in a bottom-up proteomics workflow. , 2009, Current protocols in molecular biology.

[11]  J. Solassol,et al.  Autoantibody signatures: progress and perspectives for early cancer detection , 2011, Journal of cellular and molecular medicine.

[12]  Z. Kokot,et al.  MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer , 2017, BMC Cancer.

[13]  H. Pass,et al.  Autoantibodies against tumor-associated antigens in the early detection of lung cancer. , 2016, Lung cancer.

[14]  J. Foekens,et al.  CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations , 2013, Oncotarget.

[15]  K. Makambi,et al.  Quantitative Liquid Chromatography-Mass Spectrometry-Multiple Reaction Monitoring (LC-MS-MRM) Analysis of Site-specific Glycoforms of Haptoglobin in Liver Disease* , 2013, Molecular & Cellular Proteomics.

[16]  P. Hoffmann,et al.  Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery , 2011, International journal of molecular sciences.

[17]  J. Werner,et al.  Immunotherapy as an Option for Cancer Treatment , 2017, Archivum Immunologiae et Therapiae Experimentalis.

[18]  E. Thiel,et al.  High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma. , 2007, Neuro-oncology.

[19]  J. Henion,et al.  Peer Reviewed: Sample Preparation for LC/MS/MS: Analyzing Biological and Environmental Samples , 1998 .

[20]  E. Calvo,et al.  Proteomics: New insights into rheumatic diseases , 2009, Proteomics. Clinical applications.

[21]  M. Verma Personalized Medicine and Cancer , 2012, Journal of personalized medicine.

[22]  S. Hanash,et al.  Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. , 2016, Molecular cell.

[23]  A. Walch,et al.  In Situ Metabolomics in Cancer by Mass Spectrometry Imaging , 2017, Advances in cancer research.

[24]  S. Fischer,et al.  Changes in Cancer Cell Metabolism Revealed by Direct Sample Analysis with MALDI Mass Spectrometry , 2013, PloS one.

[25]  Surinder Kaur,et al.  Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein Biotherapeutics , 2014, The AAPS Journal.

[26]  C. Proud,et al.  mTOR inhibitors in cancer therapy , 2016, F1000Research.

[27]  S. Giridharan,et al.  Is it safe for pregnant health-care professionals to handle cytotoxic drugs? A review of the literature and recommendations , 2014, Ecancermedicalscience.

[28]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[29]  Brendan Prideaux,et al.  Mass spectrometry imaging for drug distribution studies. , 2012, Journal of proteomics.

[30]  J. Bell Predicting disease using genomics , 2004, Nature.

[31]  Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging , 2016, Clinical and Translational Medicine.

[32]  Ruedi Aebersold,et al.  Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[33]  I. Berindan‐Neagoe,et al.  Zearalenone Mycotoxin Affects Immune Mediators, MAPK Signalling Molecules, Nuclear Receptors and Genome-Wide Gene Expression in Pig Spleen , 2015, PloS one.

[34]  T. Migone,et al.  A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies , 2015, Blood Cancer Journal.

[35]  S. Marx,et al.  Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1* , 2010, The Journal of Biological Chemistry.

[36]  Junfu Wei,et al.  An Optimized High Throughput Clean-Up Method Using Mixed-Mode SPE Plate for the Analysis of Free Arachidonic Acid in Plasma by LC-MS/MS , 2015, International journal of analytical chemistry.

[37]  G. Calin,et al.  Molecular Pathways Molecular Pathways : microRNAs , Cancer Cells , and Microenvironment , 2014 .

[38]  Robert W Johnson,et al.  Tissue Imaging by Mass Spectrometry: A Practical Guide for the Medicinal Chemist. , 2019, ACS medicinal chemistry letters.

[39]  S. Mathivanan,et al.  Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy , 2017, Proteomics.

[40]  H. Ressom,et al.  Metabolomic profiling of breast tumors using ductal fluid , 2016, International journal of oncology.

[41]  I. Berindan‐Neagoe,et al.  Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? , 2013, Breast.

[42]  Chuanhao Tang,et al.  Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma , 2017, PloS one.

[43]  G. Akpinar,et al.  Proteomics Analysis of Tissue Samples Reveals Changes in Mitochondrial Protein Levels in Parathyroid Hyperplasia over Adenoma. , 2017, Cancer genomics & proteomics.

[44]  R. Ahmed,et al.  mTOR Promotes Antiviral Humoral Immunity by Differentially Regulating CD4 Helper T Cell and B Cell Responses , 2016, Journal of Virology.

[45]  U. Sack,et al.  New Platform Technology for Comprehensive Serological Diagnostics of Autoimmune Diseases , 2012, Clinical & developmental immunology.

[46]  J. Yates,et al.  Protein analysis by shotgun/bottom-up proteomics. , 2013, Chemical reviews.

[47]  Ara Darzi,et al.  Chemo-informatic strategy for imaging mass spectrometry-based hyperspectral profiling of lipid signatures in colorectal cancer , 2014, Proceedings of the National Academy of Sciences.

[48]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[49]  Sanjeeva Srivastava,et al.  Proteomic databases and tools to decipher post-translational modifications. , 2011, Journal of proteomics.

[50]  R. Chiodini,et al.  The impact of next-generation sequencing on genomics. , 2011, Journal of genetics and genomics = Yi chuan xue bao.

[51]  A. Tessitore,et al.  Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors , 2013, International journal of proteomics.

[52]  J. Vermorken,et al.  Advances in the systemic treatment of head and neck cancers , 2010, Current opinion in oncology.

[53]  Y. Liu,et al.  A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease , 2015, Journal of ginseng research.

[54]  H. Fujimoto,et al.  Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer , 2018, Case Reports in Oncology.

[55]  D. Harvey,et al.  Characterization of oligosaccharide composition and structure by quadrupole ion trap mass spectrometry. , 1997, Rapid communications in mass spectrometry : RCM.

[56]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[57]  Jianxin Gu,et al.  Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer , 2017, Journal of Cancer.

[58]  B. Meiser,et al.  Quantification of Sirolimus by Liquid Chromatography-Tandem Mass Spectrometry Using On-Line Solid-Phase Extraction , 2002, Clinical chemistry and laboratory medicine.

[59]  I. Berindan‐Neagoe,et al.  TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: a pilot study. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[60]  A. Emili,et al.  Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics , 2006, Nature Protocols.

[61]  Xuan-xian Peng,et al.  Functional metabolomics: from biomarker discovery to metabolome reprogramming , 2015, Protein & Cell.

[62]  Tony Gutschner,et al.  The Dark Side of the Epitranscriptome: Chemical Modifications in Long Non-Coding RNAs , 2017, International journal of molecular sciences.

[63]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Á. Végvári Drug localizations in tissue by mass spectrometry imaging. , 2015, Biomarkers in medicine.

[65]  Dietrich A. Volmer,et al.  Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC-MS/MS. , 2014, The Analyst.

[66]  François-Michel Boisvert,et al.  Proteomics methods for subcellular proteome analysis , 2013, The FEBS journal.

[67]  Bryan P. Early,et al.  A Protease for Middle Down Proteomics , 2012, Nature Methods.

[68]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[69]  Zuofeng Li,et al.  A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis , 2016, Oncotarget.

[70]  Antonio Federico,et al.  Transcriptome Profiling in Human Diseases: New Advances and Perspectives , 2017, International journal of molecular sciences.

[71]  R. Rosell,et al.  The combination of checkpoint immunotherapy and targeted therapy in cancer. , 2017, Annals of translational medicine.

[72]  Jessica R Gooding,et al.  Metabolomics applied to the pancreatic islet. , 2016, Archives of biochemistry and biophysics.

[73]  Bih-Rong Wei,et al.  Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. , 2014, Biomarkers in medicine.

[74]  F. Vogenberg,et al.  Personalized medicine: part 1: evolution and development into theranostics. , 2010, P & T : a peer-reviewed journal for formulary management.

[75]  B. Kaplan,et al.  Strategies for the management of adverse events associated with mTOR inhibitors. , 2014, Transplantation reviews.

[76]  P. V. Van Schil,et al.  Surgical Management of Stage IIIA Non-Small Cell Lung Cancer , 2017, Front. Oncol..

[77]  H. Mischak,et al.  Mass spectrometry based proteomics in urine biomarker discovery , 2007, World Journal of Urology.

[78]  T. Veenstra,et al.  Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue , 2014, PloS one.

[79]  F Baganz,et al.  Systematic functional analysis of the yeast genome. , 1998, Trends in biotechnology.

[80]  I. Fournier,et al.  On-tissue protein identification and imaging by MALDI-Ion mobility mass spectrometry , 2010, Journal of the American Society for Mass Spectrometry.

[81]  Orli G. Bahcall Precision medicine , 2015, Nature.

[82]  Hyunsu Ju,et al.  Biomarker Discovery for Early Detection of Hepatocellular Carcinoma in Hepatitis C–infected Patients* , 2013, Molecular & Cellular Proteomics.

[83]  N. Manicke,et al.  Targeted Protein Detection Using an All-in-One Mass Spectrometry Cartridge. , 2017, Journal of the American Chemical Society.

[84]  P. Ramírez,et al.  Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation. , 2016, World journal of transplantation.

[85]  N. Barbarroja,et al.  Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases , 2008, Lupus.

[86]  T. Dassopoulos,et al.  Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease , 2018, Current Gastroenterology Reports.

[87]  R. Casadonte,et al.  MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review). , 2015, International journal of oncology.

[88]  S. Cai,et al.  Hyperplex-MRM: a hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker. , 2013, Journal of proteome research.

[89]  D. Characiejus,et al.  Prediction of response in cancer immunotherapy. , 2011, Anticancer research.

[90]  O. Dada,et al.  High-Resolution Capillary Zone Electrophoresis with Mass Spectrometry Peptide Mapping of Therapeutic Proteins: Peptide Recovery and Post-translational Modification Analysis in Monoclonal Antibodies and Antibody-Drug Conjugates. , 2017, Analytical chemistry.

[91]  R. Gomis,et al.  Proteomics in obesity research , 2009, Proteomics. Clinical applications.

[92]  X. Wang,et al.  Metabolic Profiles are Principally Different between Cancers of the Liver, Pancreas and Breast , 2014, International journal of biological sciences.

[93]  Janne Lehtiö,et al.  Mass spectrometry-based plasma proteomics: state of the art and future outlook , 2014, Expert review of proteomics.

[94]  Denis C. Bauer,et al.  A Comparative Study of Techniques for Differential Expression Analysis on RNA-Seq Data , 2014, bioRxiv.

[95]  Stefani N. Thomas,et al.  Advances in mass spectrometry-based clinical biomarker discovery , 2016, Clinical Proteomics.

[96]  Ya Zhang,et al.  Progress in the chemotherapeutic treatment of osteosarcoma. , 2018, Oncology letters.

[97]  T. Mauriala,et al.  Mass spectrometric tools for cell and tissue studies. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[98]  G. Deng,et al.  Applications of mass spectrometry in early stages of target based drug discovery. , 2006, Journal of pharmaceutical and biomedical analysis.

[99]  David A Bennett,et al.  High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. , 2005, Clinical chemistry.

[100]  P. Forget,et al.  A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research , 2017, Front. Oncol..

[101]  P. Hoffmann,et al.  Proteomics of endometrial cancer diagnosis, treatment, and prognosis , 2016, Proteomics. Clinical applications.

[102]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[103]  A. Glas,et al.  Implementation of a novel microarray‐based diagnostic test for cancer of unknown primary , 2009, International journal of cancer.

[104]  R. Jain Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[105]  Paolo Vineis,et al.  The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability , 2009, Environmental health : a global access science source.

[106]  Cornelia M van Duijn,et al.  Genome-based prediction of common diseases: advances and prospects. , 2008, Human molecular genetics.

[107]  J. Henion,et al.  Sample preparation for LC/MS/MS: analyzing biological and environmental samples. , 1998, Analytical chemistry.

[108]  S. Hanash,et al.  Mass spectrometry based proteomics for absolute quantification of proteins from tumor cells. , 2015, Methods.

[109]  U. Völker,et al.  Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma , 2014, Proteomics.

[110]  O. Shpigun,et al.  A validated LC-MS/MS method for rapid determination of methotrexate in human saliva and its application to an excretion evaluation study. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[111]  Hyewon Seo,et al.  A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[112]  R. Sallam Proteomics in Cancer Biomarkers Discovery: Challenges and Applications , 2015, Disease markers.

[113]  C. S. Allardyce,et al.  Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin. , 2002, Rapid communications in mass spectrometry : RCM.

[114]  Jeroen A. A. Demmers,et al.  Improvement of ubiquitylation site detection by Orbitrap mass spectrometry. , 2018, Journal of proteomics.

[115]  Nicola Bizzaro,et al.  Current state of diagnostic technologies in the autoimmunology laboratory , 2012, Clinical chemistry and laboratory medicine.

[116]  T. Luider,et al.  Collagen Peptides in Urine: A New Promising Biomarker for the Detection of Colorectal Liver Metastases , 2013, PloS one.

[117]  I. Berindan‐Neagoe,et al.  The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression , 2018, Cell Death & Disease.

[118]  Chibo Liu,et al.  The Application of SELDI-TOF-MS in Clinical Diagnosis of Cancers , 2011, Journal of biomedicine & biotechnology.

[119]  K. Al-Anazi,et al.  Methotrexate-Induced Acute Leukemia: Report of Three Cases and Review of the Literature , 2009, Clinical medicine. Case reports.

[120]  H. Lilja,et al.  Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring* , 2013, Molecular & Cellular Proteomics.

[121]  G. Kristiansen,et al.  Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS , 2015, BioMed research international.

[122]  K. Geoghegan,et al.  Biochemical applications of mass spectrometry in pharmaceutical drug discovery. , 2005, Mass spectrometry reviews.

[123]  Rui Chen,et al.  Promise of personalized omics to precision medicine , 2013, Wiley interdisciplinary reviews. Systems biology and medicine.

[124]  M. Vogeser,et al.  Liquid Chromatography Tandem-mass Spectrometry (LC-MS/MS) - Technique and Applications in Endocrinology , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[125]  David Baltimore,et al.  Our genome unveiled , 2001, Nature.

[126]  Jianhua Zheng,et al.  Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model , 2017, BMC Genomics.

[127]  R. Burlacu,et al.  Exposure to zearalenone mycotoxin alters in vitro porcine intestinal epithelial cells by differential gene expression. , 2015, Toxicology letters.

[128]  I. Berindan‐Neagoe,et al.  Evaluation of cellular and molecular impact of zearalenone and Escherichia coli co-exposure on IPEC-1 cells using microarray technology , 2016, BMC Genomics.

[129]  H. Olsson,et al.  Analysis of Alpha-Synuclein in Malignant Melanoma – Development of a SRM Quantification Assay , 2014, PloS one.

[130]  M. Mann,et al.  Proteomic analysis of post-translational modifications , 2003, Nature Biotechnology.

[131]  He Ren,et al.  Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis , 2016, Molecular oncology.

[132]  David J Hunter,et al.  Genomics and proteomics in epidemiology: treasure trove or "high-tech stamp collecting"? , 2006, Epidemiology.

[133]  A. Whetton,et al.  How will haematologists use proteomics? , 2007, Blood reviews.

[134]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[135]  J. von Hagen,et al.  Isolation of subcellular organelles and structures. , 2009, Methods in enzymology.

[136]  I. Duarte,et al.  Insights into the impact of silver nanoparticles on human keratinocytes metabolism through NMR metabolomics. , 2016, Archives of biochemistry and biophysics.

[137]  D. Swinkels,et al.  Immunoproteomics: From biomarker discovery to diagnostic applications , 2008, Proteomics. Clinical applications.

[138]  Ioana Berindan-Neagoe,et al.  The new era of nanotechnology, an alternative to change cancer treatment , 2017, Drug design, development and therapy.

[139]  C. Stewart,et al.  Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[140]  G A Nagana Gowda,et al.  Overview of mass spectrometry-based metabolomics: opportunities and challenges. , 2014, Methods in molecular biology.

[141]  Moyez Dharsee,et al.  Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival , 2012, PloS one.

[142]  Donald Kennedy,et al.  Breakthrough of the Year , 2007, Science.

[143]  M. Ali,et al.  Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy , 2015, International Journal of Gynecologic Cancer.

[144]  Ioana Berindan-Neagoe,et al.  Exosomes-Small Players, Big Sound. , 2018, Bioconjugate chemistry.

[145]  Youxin Wang,et al.  Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts , 2017, Oncotarget.

[146]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[147]  A. Bracher,et al.  Large FK506-Binding Proteins Shape the Pharmacology of Rapamycin , 2013, Molecular and Cellular Biology.

[148]  L. Huber,et al.  Organelle Proteomics Implications for Subcellular Fractionation in Proteomics , 2003 .

[149]  G. Hortin The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. , 2006, Clinical chemistry.

[150]  D. Kell,et al.  Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.

[151]  T. Veenstra,et al.  Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry , 2004, Proteomics.

[152]  L. Kenny,et al.  ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics , 2011 .

[153]  R. Spizzo,et al.  The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis , 2015, Gut.

[154]  G. Calin,et al.  MicroRNAome genome: A treasure for cancer diagnosis and therapy , 2014, CA: a cancer journal for clinicians.

[155]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[156]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[157]  Y. Duan,et al.  The early diagnosis and monitoring of squamous cell carcinoma via saliva metabolomics , 2014, Scientific Reports.

[158]  David Fenyö,et al.  Protein quantitation using mass spectrometry. , 2010, Methods in molecular biology.

[159]  L. Gesualdo,et al.  Management of Side Effects of Sirolimus Therapy , 2009, Transplantation.

[160]  J. Kim,et al.  Targeted Mass Spectrometric Approach for Biomarker Discovery and Validation with Nonglycosylated Tryptic Peptides from N-linked Glycoproteins in Human Plasma* , 2011, Molecular & Cellular Proteomics.

[161]  B. Tian,et al.  RNA‐Seq methods for transcriptome analysis , 2017, Wiley interdisciplinary reviews. RNA.

[162]  G. Theodoridis,et al.  Studying the effect of storage conditions on the metabolite content of red wine using HILIC LC-MS based metabolomics. , 2016, Food chemistry.

[163]  M. R. Groseclose,et al.  MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. , 2011, Bioanalysis.

[164]  S. Kanekal,et al.  Cyclophosphamide Toxicity , 1991, Drugs.

[165]  B. Döme,et al.  Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. , 2011, Journal of proteomics.

[166]  I. Berindan‐Neagoe,et al.  Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets , 2017, International journal of molecular sciences.

[167]  Richard Z. Liu,et al.  Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. , 2010, Journal of proteome research.

[168]  Emma L. Schymanski,et al.  Small Molecule Identification with MOLGEN and Mass Spectrometry , 2013, Metabolites.

[169]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[170]  Isaiah Norton,et al.  Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis , 2014, Proceedings of the National Academy of Sciences.

[171]  A. Jarmusch,et al.  Direct drug analysis from oral fluid using medical swab touch spray mass spectrometry. , 2015, Analytica chimica acta.

[172]  A. Paradiso,et al.  Genetic alterations in sporadic triple negative breast cancer. , 2018, Breast.

[173]  G. Calin,et al.  Exosomes as divine messengers: are they the Hermes of modern molecular oncology? , 2014, Cell Death and Differentiation.

[174]  Sven Diederichs,et al.  The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non‐coding RNA and synonymous mutations , 2016, EMBO molecular medicine.

[175]  Christodoulos A. Floudas,et al.  Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database , 2011, Scientific reports.

[176]  F. Slack,et al.  Junk DNA and the long non-coding RNA twist in cancer genetics , 2015, Oncogene.

[177]  X. Zheng,et al.  FKBP12-Rapamycin-associated Protein or Mammalian Target of Rapamycin (FRAP/mTOR) Localization in the Endoplasmic Reticulum and the Golgi Apparatus* , 2004, Journal of Biological Chemistry.

[178]  C. Ho,et al.  Electrospray ionisation mass spectrometry: principles and clinical applications. , 2003, The Clinical biochemist. Reviews.

[179]  G. Calin,et al.  MicroRNAs and cancer therapy - from bystanders to major players. , 2013, Current medicinal chemistry.

[180]  J. Ko,et al.  Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry. , 2014, Journal of proteomics.

[181]  E. Wang,et al.  A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. , 2013, Journal of proteomics.

[182]  A. Walch,et al.  MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice , 2015, Laboratory Investigation.

[183]  M. Molloy,et al.  A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours , 2015, BMC Cancer.

[184]  I. Berindan‐Neagoe,et al.  Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics , 2015, Acta odontologica Scandinavica.

[185]  James G. Bollinger,et al.  A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva , 2016, Proteomics.

[186]  N. Kelleher,et al.  Top Down proteomics: facts and perspectives. , 2014, Biochemical and biophysical research communications.

[187]  H. Tojo,et al.  Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.

[188]  A. Baccarelli,et al.  Global DNA Hypomethylation Is Associated with High Serum-Persistent Organic Pollutants in Greenlandic Inuit , 2008, Environmental health perspectives.

[189]  Bruno Domon,et al.  Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples , 2016, Oncotarget.

[190]  F. Blanco,et al.  Proteomic characterization of human normal articular chondrocytes: A novel tool for the study of osteoarthritis and other rheumatic diseases , 2005, Proteomics.

[191]  Robert Verpoorte,et al.  Extraction for metabolomics: access to the metabolome. , 2014, Phytochemical analysis : PCA.

[192]  F. M. Huennekens,et al.  The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. , 1994, Advances in enzyme regulation.